Clinical lymphoma, myeloma & leukemia · 2026
KMT2A-Partial Tandem Duplication Associates With Leukemia Transformation in Myelodysplastic Syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Zhao-Yu, Xie Dai-Hong, Chen Wen-Min, Wang Xu, Li Ling-Di, Hao Yue, Li Jin-Ying, Zhao Xiao-Su, Jiang Hao, Jiang Qian, Huang Xiao-Jun, Qin Ya-Zhen
Аннотация
BACKGROUND: Partial tandem duplication of KMT2A (KMT2A-PTD) is observed not only in acute myeloid leukemia (AML) but also in myelodysplastic syndrome (MDS), while the prognostic value of KMT2A-PTD in MDS needs to be clarified and the optimal therapies for these patients remains unclear.
METHODS: In this study, we analyzed 137 MDS patients with KMT2A-PTD from our hospital (PKUPH cohort) and incorporated 2493 MDS patients from the International Working Group for Prognosis in MDS (IWG-PM) cohort, among whom 65 patients had KMT2A-PTD.
RESULTS: MDS patients with KMT2A-PTD in IWG-PM cohort had significantly higher blast percentage and IPSS-R score than those without KMT2A-PTD. The 3-year cumulative incidence of leukemia transformation in MDS patients with KMT2A-PTD from both PKUPH and IWG-PM cohort was significantly higher than that in MDS patients without KMT2A-PTD (49.8% [95% CI, 38.6%-61.1%] vs. 19.3% [95% CI, 17.5%-21.2%], P < .001; 58.3% [95% CI, 43.1%-73.5%] vs. 19.3% [95% CI, 17.5%-21.2%], P < .001), respectively. Multivariate analysis in the IWG-PM cohort showed that KMT2A-PTD was an independent poor predictor for leukemia transformation (P < .001). None of co-occurring gene mutations significantly influenced the risk of leukemia transformation in MDS patients with KMT2A-PTD. A landmark analysis in PKUPH cohort suggested that allogenic hematopoietic stem cell transplantation (allo-HSCT) significantly reduced the cumulative incidence of leukemia transformation (P < .001) and the cumulative incidence of relapse (17.6% [95% CI, 5.1%-28.7%] vs. 100% [95% CI, 51.0%-100%], P < .001), respectively.
CONCLUSION: KMT2A-PTD may identify a distinct MDS subgroup characterized by a high risk of leukemia transformation, and allo-HSCT could improve outcomes of MDS patients with KMT2A-PTD.
METHODS: In this study, we analyzed 137 MDS patients with KMT2A-PTD from our hospital (PKUPH cohort) and incorporated 2493 MDS patients from the International Working Group for Prognosis in MDS (IWG-PM) cohort, among whom 65 patients had KMT2A-PTD.
RESULTS: MDS patients with KMT2A-PTD in IWG-PM cohort had significantly higher blast percentage and IPSS-R score than those without KMT2A-PTD. The 3-year cumulative incidence of leukemia transformation in MDS patients with KMT2A-PTD from both PKUPH and IWG-PM cohort was significantly higher than that in MDS patients without KMT2A-PTD (49.8% [95% CI, 38.6%-61.1%] vs. 19.3% [95% CI, 17.5%-21.2%], P < .001; 58.3% [95% CI, 43.1%-73.5%] vs. 19.3% [95% CI, 17.5%-21.2%], P < .001), respectively. Multivariate analysis in the IWG-PM cohort showed that KMT2A-PTD was an independent poor predictor for leukemia transformation (P < .001). None of co-occurring gene mutations significantly influenced the risk of leukemia transformation in MDS patients with KMT2A-PTD. A landmark analysis in PKUPH cohort suggested that allogenic hematopoietic stem cell transplantation (allo-HSCT) significantly reduced the cumulative incidence of leukemia transformation (P < .001) and the cumulative incidence of relapse (17.6% [95% CI, 5.1%-28.7%] vs. 100% [95% CI, 51.0%-100%], P < .001), respectively.
CONCLUSION: KMT2A-PTD may identify a distinct MDS subgroup characterized by a high risk of leukemia transformation, and allo-HSCT could improve outcomes of MDS patients with KMT2A-PTD.